Michael F. MacLean
CIK: 0001383731
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Apr 1, 2026CAMP
Camp4 Therapeutics Corp
Award(A)DirectStock Option (Right to Buy)
56K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Direct134K shares- - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.8K shares at avg. $72.45$131K - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.7K shares at avg. $72.45$198K - Jan 7, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2K shares at avg. $72.23$143K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct30.9K shares at avg. $42.73$1.3M - Jul 25, 2025VERV
Verve Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
42.2K shares- - Jul 25, 2025VERV
Verve Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
136.1K shares- - Jun 5, 2025VERV
Verve Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
42.2K shares- - Mar 20, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct7.9K shares at avg. $31.06$246K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.6K shares at avg. $28.59$46K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.7K shares at avg. $28.59$48K - Jan 6, 2025RNA
Avidity Biosciences, Inc.
Award(A)Direct25K shares- - Dec 18, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct11.2K shares at avg. $32.66$364K - Nov 6, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct27.3K shares at avg. $46.22$1.3M - Nov 6, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct13.9K shares at avg. $45.33$629K - Nov 6, 2024RNA
Avidity Biosciences, Inc.
Exercise(M)Direct13.9K shares at avg. $6.57$91K - Nov 6, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct65.2K shares at avg. $45.33$3.0M - Nov 6, 2024RNA
Avidity Biosciences, Inc.
Exercise(M)Direct65.2K shares at avg. $8.82$575K - Sep 23, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct11.5K shares at avg. $44.00$506K - Sep 19, 2024RNA
Avidity Biosciences, Inc.
Award(A)Direct25K shares- - Sep 19, 2024RNA
Avidity Biosciences, Inc.
Award(A)Direct25K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 1, 2026 |  CAMP Camp4 Therapeutics Corp | Award(A) Stock Option (Right to Buy) | 56,000 | - | - | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition(D) | 133,977 | - | $0 | Direct |
| Jan 21, 2026 |  RNA Avidity Biosciences, Inc. | Sale(S) | 1,807 | $72.45 | $130,917 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,735 | $72.45 | $198,151 | Direct |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,974 | $72.23 | $142,582 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 30,914 | $42.73 | $1,320,844 | Direct |
| Jul 25, 2025 |  VERV Verve Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 42,200 | - | - | Direct |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 136,139 | - | - | Direct |
| Jun 5, 2025 | VERV Verve Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 42,200 | - | - | Direct |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 7,935 | $31.06 | $246,425 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,622 | $28.59 | $46,378 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,665 | $28.59 | $47,608 | Direct |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | Award(A) | 25,000 | - | $0 | Direct |
| Dec 18, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 11,151 | $32.66 | $364,192 | Direct |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 27,262 | $46.22 | $1,260,017 | Direct |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 13,875 | $45.33 | $629,008 | Direct |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | Exercise(M) | 13,875 | $6.57 | $91,159 | Direct |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 65,182 | $45.33 | $2,954,954 | Direct |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | Exercise(M) | 65,182 | $8.82 | $574,905 | Direct |
| Sep 23, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 11,510 | $44.00 | $506,440 | Direct |
| Sep 19, 2024 | RNA Avidity Biosciences, Inc. | Award(A) | 25,000 | - | $0 | Direct |
| Sep 19, 2024 | RNA Avidity Biosciences, Inc. | Award(A) | 25,000 | - | $0 | Direct |
1-22 of 22 transactions
About MacLean Michael F
MacLean Michael F (SEC CIK 0001383731) files insider reports with the SEC as Director of Research Alliance Corp III (RACC), Director of Camp4 Therapeutics Corp (CAMP) and Chief Financial Officer of Avidity Biosciences, Inc. (RNAM). Signal8 also holds filings tied to 1 other company.
Signal8 holds 15 ownership filings by MacLean Michael F (2 Form 3, 13 Form 4), filed between Sep 23, 2024 and May 19, 2026. Those filings report 22 transactions, from Sep 19, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MacLean Michael F's filings is in CAMBRIDGE, MA.
Recent filings by MacLean Michael F
- Apr 1, 2026: Grant or award of CAMP derivative securities (Form 4, code A).
- Feb 27, 2026: Disposition to issuer transaction of RNAM shares (Form 4, code D).
- Jan 21, 2026: Open-market sales of RNA shares (2 lines, Form 4, code S).
- Jan 7, 2026: Open-market sale of RNA shares (Form 4, code S).
- Aug 6, 2025: Open-market sale of RNA shares (Form 4, code S).
Other insiders filing for Research Alliance Corp III (RACC)
- Research Alliance Holdings III LLC /Cayman, Director
- Hammond Matthew, Chief Executive Officer
- Miller Timothy J, Director
- Stusnick Henry William, COO and CBO
- Adams Francis Sherman, Chief Financial Officer